title: Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics.
abstract: The aim of this study was to determine the prevalence of osteopenia in schizophrenic patients with hyperprolactinemia and to identify factors influencing bone density. Our results indicate that low bone mineral density was highly prevalent in a chronic psychiatric population treated with prolactin-elevating antipsychotics. Identified risk factors appear to be age and hyperprolactinemia for both females and males.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, Indiana 46285, USA.
authors.forename: Hong
authors.initials: H
authors.lastname: Liu-Seifert
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Kinon
authors.forename: Jonna
authors.initials: J
authors.lastname: Ahl
authors.forename: Shaw
authors.initials: S
authors.lastname: Lamberson
mesh_terms: D000328:Adult; D000375:Aging / Q000502:physiology*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000097:blood* / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology; D011388:Prolactin / Q000097:blood*; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood* / Q000150:complications* / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D011388:Prolactin